임상시험 트래커
추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov
기업
18건 표시
- 4상모집 중· Hidradenitis Suppurativa (HS)Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa
리드: 노바티스
- 4상모집 중· Atherosclerotic Cardiovascular DiseaseStudy to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dyslipidemia
리드: 노바티스
- 4상모집 중· Graft vs. Host DiseaseStudy of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease
리드: 노바티스
- 4상모집 중· Drug InteractionsLDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering
협력: 노바티스
- 4상모집 중· Relapsing Remitting Multiple Sclerosis (RRMS)ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS
리드: 노바티스
- 4상모집 중· Plaque, AtheroscleroticIntravascular Imaging Study of the Effect of Inclisiran on Plaque in Patients With Acute Myocardial Infarction
리드: 노바티스
- 4상모집 중· Steroid-refractory Acute Graft Versus Host DiseaseStudy of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease
리드: 노바티스
- 4상모집 중· Ankylosing Spondylitis (AS)A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis
협력: 노바티스
- 4상모집 중· Prostate CancerLong-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
리드: 노바티스
- 4상모집 중· Sickle Cell DiseaseRollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
리드: 노바티스
- 4상모집 중· Multiple SclerosisSafety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis
리드: 노바티스
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.